Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

التفاصيل البيبلوغرافية
العنوان:	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
المؤلفون:	Xu, Naiqing, Fang, Wenfeng, Mu, Libing, Tang, Yanna, Gao, Lei, Ren, Shengxiang, Cao, Dengfeng, Zhou, Lixin, Zhang, Aiqun, Liu, Deruo, Zhou, Caicun, Wong, Kwok-Kin, Yu, Lei, Zhang, Li, Chen, Liang
المساهمون:	Chen, L (reprint author), Peking Union Med Coll, Grad Sch, Beijing 100021, Peoples R China., Chen, L (reprint author), Natl Inst Biol Sci, Beijing, Peoples R China., Chen, L (reprint author), Chinese Acad Med Sci, Beijing 100730, Peoples R China., Zhang, L (reprint author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China., Chen, L (reprint author), Collaborat Innovat Ctr Canc Med, Natl Inst Biol Sci, Beijing, Peoples R China., Peking Union Med Coll, Grad Sch, Beijing 100021, Peoples R China., Natl Inst Biol Sci, Beijing, Peoples R China., Chinese Acad Med Sci, Beijing 100730, Peoples R China., Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China., Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China., Shanghai Pulm Hosp, Shanghai, Peoples R China., Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China., Peking Univ, Canc Hosp, Beijing 100871, Peoples R China., Gen Hosp Peoples Liberat Army, Beijing, Peoples R China., China Japan Friendship Hosp, Dept Thorac Surg, Beijing, Peoples R China., Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA., Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China., Collaborat Innovat Ctr Canc Med, Natl Inst Biol Sci, Beijing, Peoples R China.
المصدر:	PubMed ; SCI
بيانات النشر:	ONCOTARGET
سنة النشر:	2016
المجموعة:	Peking University Institutional Repository (PKU IR) / 北京大学机构知识库
مصطلحات موضوعية:	EGFR, transgenic mouse model, tyrosine kinase inhibitor, lung cancer, GROWTH-FACTOR-RECEPTOR, RANDOMIZED PHASE-3 TRIAL, KINASE DOMAIN MUTATIONS, GENE COPY NUMBER, 1ST-LINE TREATMENT, OPEN-LABEL, GEFITINIB SENSITIVITY, MOLECULAR PREDICTORS, EXPRESSION, ERLOTINIB
الوصف:	Current guidelines for lung cancer treatment with EGFR tyrosine kinase inhibitors (TKI) include only patients with mutated EGFR, although some patients with wildtype EGFR (wt-EGFR) have exhibited positive responses to this therapy as well. Biomarkers predicting the benefit from EGFR-TKIs treatment remain to be determined for patients with wild-type EGFR. Here, we report that wt-EGFR overexpression transformed cells in vitro and induced tumorigenesis in vivo in transgenic mouse models. Wt-EGFR driven lung cancer was hypersensitive to TKI treatment in mouse model. Lung cancer patients with high-expression of wt-EGFR showed longer Overall Survival in comparison to low-expression patients after TKI treatment. Our data therefore suggest that treatment with EGFR inhibitors should be extended to include not only patients with mutated EGFR but also a subset of patients with overexpression of wt-EGFR. ; Chinese Ministry of Science and Technology grant (973 grant) [2011CB812401]; National Natural Science Foundation of China [81472606]; Beijing Municipal Government ; SCI(E) ; PubMed ; ARTICLE ; zhangli@sysucc.org.cn; chenliang@nibs.ac.cn ; 4 ; 3884-3896 ; 7
نوع الوثيقة:	journal/newspaper
اللغة:	English
تدمد:	1949-2553
Relation:	ONCOTARGET.2016,7,(4),3884-3896.; 1392115; http://hdl.handle.net/20.500.11897/435973; WOS:000369952400019
DOI:	10.18632/oncotarget.6461
الاتاحة:	https://hdl.handle.net/20.500.11897/435973 https://doi.org/10.18632/oncotarget.6461
رقم الانضمام:	edsbas.459636FB
قاعدة البيانات:	BASE

View record in BASE

Full Text Finder

الوصف
تدمد:	19492553
DOI:	10.18632/oncotarget.6461